A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease

Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of GV-971 in mild to moderate Alzheimer's disease.

Timeline

Start

2020-10-27

Primary completion

2025-12

Completion

2026-10

Outcome

Met primary endpoint

Stopped: “The quality of study was seriously affected by the COVID-19, so it was decided to suspend the trial and restart it at the right time.”

release “在去年结束的为期36周、多中心、随机、双盲、治疗轻、中度AD患者的临床3期实验中，GV-971能够明显改善轻、中度AD患者的认知功能障碍。” greenvalleypharma.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sodium Oligomannate	Oligonucleotide (other)	—	Oral

Indications